This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer¿statistics and epidemiology of lung cancer¿along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer¿immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.

1 Lung Cancer Statistics.- 2 Epidemiology of Lung Cancer.- 3 Lung Cancer In Never Smokers.- 4 Immune Therapy.- 5 Anti-angiogenesis in personalized therapy of lung cancer.- 6 Target therapy in Lung Cancer.- 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: an update.- 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.- 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.- 10 Chemotherapy Resistance in Lung Cancer.- 11 Current state of metal-based drugs for the efficient therapy of lung cancers and lung metastases.

Aamir Ahmad, PhD, is a Scientist at the Wayne State University School of Medicine, Department of Pathology, and the Karmanos Cancer Institute. He has been a member of leading cancer organizations such as the American Association for Cancer Reseasrch and the Union for International Cancer Control. In addition to serving as a reviewer for a number of peer-reviewed scientific journals, he is currently a Section Editor for the journal PLoS ONE, for which he is responsible for policy drafts and the identification and management of special issues. Dr. Ahmad has published more than 100 scientific papers and has authored numerous book chapters. In addition to the current volume Dr. Ahmad served as the editor of two volumes published by Springer. 

Shirish M. Gadgeel, M.D. a Professor in the Department of Oncology at Karmanos Institute/Wayne State University in Detroit. He is the co-leader of the Molecular Therapeutics Program of Karmanos Cancer Institute and the leader of the Multidisciplinary Thoracic Oncology team. Dr. Gadgeel is a member of several professional societies, including the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He currently serves on the Editorial Board of the journals Cancer and Clinical Lung Cancer. Dr. Gadgeel is a Principal Investigator of several trials focused on the treatment of Lung Cancer, and has published more than 80 scientific papers